Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

(2021) Ellen Q. Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Eric L Simpson et al.   LANCET

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

(2020) Jonathan I. Silverberg et al.   JAMA Dermatology

15433 Assessment of cytochrome P450 3A inhibition and induction of abrocitinib: Midazolam drug-drug interaction (DDI) study and oral contraceptive DDI study

(2020) Xiaoxing Wang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

(2019) Melinda J. Gooderham et al.   JAMA Dermatology

Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study

(2018) Elena Peeva et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

(2018) Michael L. Vazquez et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

(2015) Florence Namour et al.   CLINICAL PHARMACOKINETICS

Which Human Metabolites Have We MIST? Retrospective Analysis, Practical Aspects, and Perspectives For Metabolite Identification and Quantification in Pharmaceutical Development

(2009) Laurent Leclercq et al.   CHEMICAL RESEARCH IN TOXICOLOGY